Kyto Biopharma, Inc. Confirms Definitive Isolation of the Human Vitamin B12 Receptor (TCblR)
11/21/2007 11:23:56 AM
TORONTO--(BUSINESS WIRE)--Kyto Biopharma Inc. (OTCBB:KBPH), (“Kyto”), a biotechnology company focused on developing monoclonal antibody based therapeutic agents for cancer treatment, announced today that for the first time it has conclusively isolated the protein and gene encoding the human Vitamin B12 receptor - TCblR for the cellular uptake of the transcobalamin-bound Vitamin B12. The over expression of TCblR in cancer cells provides the rationale for targeting the Vitamin B12 receptor in the treatment of various forms of cancer.
comments powered by